SGEN Stock Overview Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. More details
Rewards Risk Analysis No risks detected for SGEN from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Seagen Historical stock prices Current Share Price US$228.74 52 Week High US$228.96 52 Week Low US$123.77 Beta 0.32 1 Month Change 7.86% 3 Month Change 9.76% 1 Year Change 76.48% 3 Year Change 13.72% 5 Year Change 336.44% Change since IPO 2,672.61%
Recent News & Updates
Seagen Inc. Files Form 15 Dec 26 Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index (USD) Pfizer Inc. (NYSE:PFE) completed the acquisition of Seagen Inc. (NasdaqGS:SGEN) from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others. Dec 14
Seagen Inc. Announces Phase 2 Study Evaluating the Antibody-Drug Conjugate ADCETRIS (brentuximab Vedotin) in Combination with the PD-1 Inhibitor Nivolumab and Standard Chemotherapy Agents Doxorubicin and Dacarbazine Dec 11
Seagen Inc. Announces Data from the Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA Dec 06 Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer Dec 02
See more updates
Seagen Inc. Files Form 15 Dec 26 Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index (USD) Pfizer Inc. (NYSE:PFE) completed the acquisition of Seagen Inc. (NasdaqGS:SGEN) from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others. Dec 14
Seagen Inc. Announces Phase 2 Study Evaluating the Antibody-Drug Conjugate ADCETRIS (brentuximab Vedotin) in Combination with the PD-1 Inhibitor Nivolumab and Standard Chemotherapy Agents Doxorubicin and Dacarbazine Dec 11
Seagen Inc. Announces Data from the Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA Dec 06 Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer Dec 02
Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer Dec 01
Chief Technical Officer notifies of intention to sell stock Nov 12
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting Nov 04
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 02
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 02 Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial
Seagen Inc. Announces to Highlight Overall Survival Data for Padcev and Tivdak During Presidential Symposium At Esmo Congress 2023 Oct 17
Seagen Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 13
Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial Sep 23
Chief Technical Officer notifies of intention to sell stock Sep 10 Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy Sep 05
Insider notifies of intention to sell stock Aug 18
Seagen Inc. Announces Phase 3 HER2CLIMB-02 Clinical Trial of TUKYSA®? (tucatinib) in Combination with Antibody-Drug Conjugate Ado-Trastuzumab Emtansine Aug 17
Consensus EPS estimates fall by 12%, revenue upgraded Aug 09
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 02
Seagen Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 13
Seagen Inc. Announces Phase 3 Trial of Adcetris (Brentuximab Vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% Vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma Jun 21
Seagen Announces ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 98% Overall Response Rate and 93% Complete Response Rate in Patients with Early-Stage Classical Hodgkin Lymphoma (cHL) Jun 13
Chief Technical Officer notifies of intention to sell stock Jun 11
Independent Director notifies of intention to sell stock May 18
Independent Director notifies of intention to sell stock May 05
First quarter 2023 earnings: EPS misses analyst expectations Apr 29
Price target increased by 7.3% to US$216 Apr 27
Insider notifies of intention to sell stock Apr 21
Chief Financial Officer exercised options and sold US$8.8m worth of stock Apr 13
Independent Director notifies of intention to sell stock Apr 09
Price target increased by 7.7% to US$181 Mar 14
Chief Financial Officer notifies of intention to sell stock Mar 13
Chief Financial Officer notifies of intention to sell stock Mar 03
Consensus EPS estimates fall by 22% Feb 24
Independent Director exercised options to buy US$1.4m worth of stock. Feb 19
Full year 2022 earnings: EPS and revenues exceed analyst expectations Feb 17
President of Research & Development notifies of intention to sell stock Feb 06
President of Research & Development notifies of intention to sell stock Jan 29
Chief Legal Officer notifies of intention to sell stock Jan 23 Seagen Inc. to Report Q4, 2022 Results on Feb 15, 2023
President of Research & Development notifies of intention to sell stock Jan 09 Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer Dec 21
Independent Director exercised options to buy US$1.1m worth of stock. Dec 16
Seagen Inc. Announces Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) with Novel Immunotherapy Combination in Patients with Advanced- and Early-Stage Classical Hodgkin Lymphoma Dec 13
Price target decreased to US$166 Nov 22
Chief Legal Officer exercised options to buy US$171k worth of stock. Nov 19
Independent Director recently sold US$968k worth of stock Nov 18 Seagen Inc. Announces U.S. FDA Approval of New Indication for Adcetris® (Brentuximab Vedotin) for Children with Previously Untreated High Risk Hodgkin Lymphoma
Price target decreased to US$169 Nov 01
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Oct 28
Seagen Inc. Revises Revenue Guidance for the Full Year of 2022 Oct 28
Chief Medical Officer & Interim CEO notifies of intention to sell stock Oct 21
Seagen Inc. to Report Q3, 2022 Results on Oct 27, 2022 Oct 07
Seagen: A Stellar Portfolio Anchor Oct 04
Seagen in licensing deal with Lava Therapeutics for cancer candidate Sep 26
Seagen Inc. Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer Sep 20
Seagen ticks lower as management suggests it could look at acquisitions Sep 14
Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (Enfortumab Vedotin-Ejfv) with KEYTRUDA((R) (Pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer Sep 13
Seagen to Highlight Research in Urothelial and Colorectal Cancers At 2022 European Society for Medical Oncology (Esmo) Congress Sep 08
Chief Medical Officer & Interim CEO notifies of intention to sell stock Sep 04
Merck’s Reportedly Talks to Acquire Seagen Hit Snag, Threatening Mega Pharma Deal Aug 27
Merck's talks with Seagen said to hit obstacle over price - report Aug 26
Arbitrator Rules in Favor of Daiichi Sankyo Company, Limited in Dispute with Seagen Inc Aug 13
Seagen falls as arbitrator rules in favor of Daiichi Sankyo Aug 12 Shareholder Returns SGEN US Biotechs US Market 7D 4.5% -5.6% -3.5% 1Y 76.5% -1.5% 22.1%
See full shareholder returns
Return vs Market: SGEN exceeded the US Market which returned 20.8% over the past year.
Price Volatility Is SGEN's price volatile compared to industry and market? SGEN volatility SGEN Average Weekly Movement 1.8% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: SGEN has not had significant price volatility in the past 3 months.
Volatility Over Time: SGEN's weekly volatility (2%) has been stable over the past year.
About the Company Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases.
Show more Seagen Inc. Fundamentals Summary How do Seagen's earnings and revenue compare to its market cap? SGEN fundamental statistics Market cap US$43.15b Earnings (TTM ) -US$750.22m Revenue (TTM ) US$2.30b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SGEN income statement (TTM ) Revenue US$2.30b Cost of Revenue US$2.13b Gross Profit US$171.59m Other Expenses US$921.81m Earnings -US$750.22m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/12/15 09:03 End of Day Share Price 2023/12/13 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Seagen Inc. is covered by 34 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ishan Majumdar Baptista Research Emily Bodnar Berenberg George Farmer BMO Capital Markets Equity Research
Show 31 more analysts 
